HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife Survey Points To Emphasizing Digital For Growing Asia-Pacific Sales

Executive Summary

Survey of more than 5,000 Asia-Pacific consumers finds 56% use technology tools such as nutrition apps to support healthy living, suggesting opportunity to connect with consumers.

You may also be interested in...



Herbalife Relaunches To ‘2.0’ With 'Unified, Global Platform' After Sales Fall 10.3% In 2022

Direct seller announces relaunch after year-long sales slump blamed on macroeconomic inflationary pressures. No full-year guidance due to rapidly shifting macroeconomic environment and increased market volatility.

US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?

Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.

Twice Retired Herbalife CEO Johnson Returns To Helm For $1 Salary Plus Stock Incentives

Michael Johnson previously was CEO from 2003 to 2017 and from 2019 to early 2020, as well as chairman from 2007 to early 2020. Direct seller granted him an equity-based long-term incentive plan in stock appreciation rights and restricted stock units.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel